We haven’t yet seen the actual data but a 20% reduction of cardiovascular events in a 17, 500 participant randomized trial of a GLP-1 anti-obesity drug is a big deal and likely will change the reimbursement landscape (and further promote uptake)
We haven’t yet seen the actual data but a 20% reduction of cardiovascular events in a 17, 500 participant randomized trial of a GLP-1 anti-obesity drug is a big deal and likely will change the reimbursement landscape (and further promote uptake)
No replies yet.